Livagen: KEDA molecular and hepatocyte-use claims — US7101854B2
Vladimir Khatskelevich Khavinson · 2006 · US7101854B2 · patent family 20240745
Published 2006-09-05.
Reported patent results
Reported findings
The patent reports changes in selected liver and immune markers during treatment.
Livagen/KEDA patent example in 23 patients aged 32–53 with chronic persistent hepatitis; before/after, without a clear untreated comparator.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bilirubin | 26.3 ± 1.8 → 21.7 ± 1.5 | Source table’s blanket units are questionable for different analytes, so no unit correction is invented · p<0.05 |
| ALT | 53.1 ± 4.7 → 40.8 ± 3.1 | Before/after; no established controlled treatment effect · p<0.05 |
| IgM | 3.80 ± 0.06 → 1.50 ± 0.03 g/L | Before/after · p<0.05 |
| Other chemistry | AST 39.4 ± 3.7 → 38.5 ± 2.4; cholesterol 4.9 ± 0.5 → 5.1 ± 0.3 | Not marked significant in the table; selective positive reporting avoided |
Uncontrolled marker changes do not prove liver regeneration, prevention of hepatocyte death or clinical disease modification. Published/patent versions may describe the same observations.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The claims specify Lys-Glu-Asp-Ala and compositions or uses directed at hepatocyte function.
Molecular identity and a patent use claim do not establish treatment of human liver disease.
- Publication
- US7101854B2 ↗ · 2006-09-05
- Earliest priority / filing
- 2000-10-09 / 2001-05-15
- Original applicant / assignee
- Nostiji "Klinika Instituta Bioregulyatsii Gerontologii" OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 20240745 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide stimulating the functional activity of hepatocytes, pharmacological substance on its basis and the method of its application
Inventors: Vladimir Khatskelevich Khavinson.
US7101854B2 · EP1325026B1 · ATE273994T1 · AU2001266441A1 · CA2425445C · DE60105042T2 · RU2166957C1 · WO2002030955A2
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Molecular identity and a patent use claim do not establish treatment of human liver disease.
- Uncontrolled marker changes do not prove liver regeneration, prevention of hepatocyte death or clinical disease modification. Published/patent versions may describe the same observations.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20240745. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladimir Khatskelevich Khavinson. Livagen: KEDA molecular and hepatocyte-use claims — US7101854B2 US7101854B2 · patent family 20240745 2006.
Molekul research summary: https://molekul.io/research/patent-us7101854b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry